[Pharmacological properties of simeprevir (SOVRIAD® capsules 100 mg), a new drug for the treatment of hepatitis C, and results of its clinical studies].
Kenji
K
Nagino
Kenichiro
K
Tsutsumi
Miwako
M
Ishido
Yasushi
Y
Harada
D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D002214:Capsules / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006526:Hepatitis C / Q000188:drug therapy*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D000069616:Simeprevir; D013449:Sulfonamides / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D017361:Viral Nonstructural Proteins / Q000737:chemistry / Q000378:metabolism; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
D000998:Antiviral Agents; D002214:Capsules; D006575:Heterocyclic Compounds, 3-Ring; D000069616:Simeprevir; D013449:Sulfonamides; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C093542:NS4 protein, hepatitis C virus